YAP-TEAD Inhibitor 1 (Peptide 17) YAP-TEAD Inhibitor 1 inhibitor blocks TNFR1-mediated cytotoxicity
Copy code to add this image to your page
Tumor necrosis factor receptor 1 (TNFR1) drives essential cellular signaling cascades in chronic inflammatory states and autoimmune pathologies. Ligand binding to extracellular cysteine-rich domains triggers receptor trimerization. This event initiates downstream assembly of multiprotein intracellular signaling complexes. The canonical interaction between TNFα and TNFR1 mediates signaling outcomes through Complex I formation or through secondary cytotoxic death complexes. Beyond TNFα, secondary endogenous ligands act on TNFR1. These ligands include peptidoglycan recognition protein 1 complexes with heat shock protein 70 (Tag7-Hsp70) as well as DNA-binding autoantibodies. Pathological activation of TNFR1 by these diverse drivers culminates in persistent tissue injury. Targeted receptor antagonism represents a direct strategy to suppress cytotoxic cascades without global immune suppression.
The synthetic peptide derivative YAP-TEAD Inhibitor 1 (Peptide 17), corresponding to an 8-mer fragment (sequence RSNYVLKG) derived from the C-terminal domain of innate immunity protein Tag7/PGLYRP1, functions as a direct extracellular antagonist. Biochemical characterization indicates that this peptide sequence engages TNFR1 with elevated selectivity. The molecule operates as a competitive inhibitor of receptor-ligand engagement. By physically occupying binding interfaces on extracellular receptor domains, the YAP-TEAD Inhibitor 1 inhibitor prevents trimeric TNFα engagement. Additionally, the peptide blocks cytotoxic interactions mediated by Tag7-Hsp70 heterocomplexes and pathogenic DNA-binding autoantibodies. Biological assays confirm that this competitive occupancy suppresses ligand-induced conformational changes.
In vitro cellular assays demonstrate robust blockade of distinct programmed cell death pathways. Under tested cellular conditions, exposure to cytotoxic concentrations of TNFα, Tag7-Hsp70, or autoantibodies triggers caspase-dependent apoptosis and RIPK1/RIPK3-dependent necroptosis. Treatment with YAP-TEAD Inhibitor 1 (Peptide 17) maintains high cell viability. Caspase-3 cleavage was markedly reduced across treated cell populations. Similarly, phosphorylation of RIPK3 and downstream MLKL executing necroptosis was suppressed. These observations confirm dual protection against apoptotic and necroptotic death pathways. Target engagement occurs at physiologically relevant nanomolar concentrations without intrinsic cellular toxicity.
Preclinical evaluation in rodent models provides empirical evidence of therapeutic efficacy in vivo. In a murine model of complete Freund's adjuvant (CFA)-induced arthritis, administration of the 17.1A peptide significantly modified local and systemic disease indicators. Hind paw swelling decreased substantially within days of treatment initiation. Elevated local tissue temperatures and systemic fever responses were effectively attenuated. Histological evaluation of inflamed joint tissue revealed marked reductions in synovial hypercellularity, inflammatory cell infiltration, and periarticular soft tissue edema.
Structural preservation of joint cartilage and underlying bone represents a critical therapeutic endpoint in inflammatory arthritis models. In untreated adjuvant arthritis control mice, persistent intra-articular cytokine signaling induces severe chondrocyte loss and subchondral bone erosion. In contrast, animals receiving the peptide exhibited preserved proteoglycan matrix density within articular cartilage. Osteoclast numbers along the bone-pannus interface remained low. These empirical findings indicate that blocking TNFR1 signal transduction at the extracellular receptor interface protects against structural tissue degradation. The approach offers a viable paradigm for disease-modifying intervention in inflammatory autoimmune disease contexts, as described in contemporary analyses of TNF receptor superfamily signaling targeted therapeutics.
Pharmacological Evaluation of Antagonistic Peptide Fragments
Copy code to add this image to your page
YAP-TEAD Inhibitor 1 (Peptide 17) acts as a targeted antagonist of TNFR1. Utilizing an 8-mer sequence (RSNYVLKG) derived from Tag7/PGLYRP1, the peptide competitively blocks TNFR1 binding to cytotoxic ligands such as TNFα, Tag7-Hsp70, and autoantibodies. This target engagement inhibits both apoptotic and necroptotic signaling pathways in vitro. In vivo administration attenuates local paw swelling, thermal dysregulation, synovitis, and osteochondral damage in murine adjuvant arthritis models.
Competitive Suppression of Cytotoxic Signaling Cascades in Vitro
Target engagement assays confirm that YAP-TEAD Inhibitor 1 (Peptide 17) binds extracellular domains of TNFR1 with nanomolar affinity. This binding prevents ligand-induced receptor assembly. Cytotoxic assays were performed across multiple cell lines challenged with TNFα, Tag7-Hsp70, or autoimmune complexes. Cell survival remained high in treated groups. Mechanistic markers showed clear attenuation. In particular, application of the YAP-TEAD Inhibitor 1 inhibitor reduced pro-apoptotic caspase-8 cleavage to baseline levels under tested in vitro conditions. Parallel necroptotic cascades were blocked. Phosphorylation of RIPK1 and MLKL was virtually absent in treated cell lysates. These findings confirm dual inhibition of distinct necrotic and apoptotic signaling routes.
Attenuation of CFA-Induced Synovitis and Structural Joint Damage
In vivo activity was assessed using a murine CFA-induced arthritis model. Systemic administration of the 8-mer peptide fragment yielded prominent anti-inflammatory effects. Hind paw volume decreased significantly over the observation period. Local hyperthermia and systemic thermal elevations normalized rapidly. Histopathological scoring revealed reduced leukocyte infiltration into synovial membranes. Periarticular tissue edema subsided. Crucially, micro-computed tomography and histological staining demonstrated structural protection of joint architecture. Articular cartilage destruction was minimal compared to vehicle controls. Subchondral bone resorption was prevented. Within this murine model, target engagement of TNFR1 directly protects structural joint integrity.